Kevin Caldwell, Ossium’s Co-Founder & CEO, was featured on the latest podcast from Flux. Kevin chats with Flux’s Alice Lloyd George about Ossium’s mission, the history of bone marrow transplants, and the future of medicine.
Co-Founder, President & CEO, Kevin Caldwell talks about the mission and inspiration of Ossium Health in a recent Venture Stories podcast hosted by Village Global.
3DHEALS invites technological game-changers, entrepreneurs, venture capitalists, world-class clinicians, scientists, and other expert stakeholders to have deep-dive conversations on how to re-invent healthcare using 3D printing, bioprinting, and related emerging technologies.
Dr. Jenny Chen speaks with our Co-Founder, President, and CEO, Kevin Caldwell, about Kevin’s personal journey as an entrepreneur, how such a bone marrow/stem cell band from organ donors can help biofabrication and tissue engineering, and the bioethical concerns with cell therapy and tissue engineering. The video version of this interview can be found here.
The National Institutes of Health notified Ossium that its proposal to demonstrate that the pool of viable, deceased donors for bone marrow transplants includes tissue donors — deceased donors who do not satisfy all of the health requirements of organ donors — is likely to be accepted. The NIH‘s decision to support Ossium’s research could eventually unlock substantial funding for a project that could dramatically expand the pool of viable deceased bone marrow donors, enabling thousands of additional patients to receive lifesaving stem cell transplants each year.
Leading venture capital firm First Round Capital — early investors in Uber, Square, Flatiron Health and more than 250 other companies — has backed Ossium Health. The San Francisco, New York, and Philadelphia based VC specializes in early stage companies, pairing its “seed investments” with a suite of company-building services for its portfolio companies.
Recent Comments